Showing results (221-230 of 316) with videos related to

Sort By:
Pageof 32
Lancet (London, England)|May 20, 2014
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialMolebogeng X Rangaka, Robert J Wilkinson, Andrew Boulle, et al.
Blood|September 27, 2014
Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in miceJose A Guerrero, Cavan Bennett, Louise van der Weyden, et al.
The Lancet. Global Health|September 17, 2021
BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trialJudith R Glynn, Katherine Fielding, Themba Mzembe, et al.
BMJ Global Health|July 19, 2021
Effect of door-to-door distribution of HIV self-testing kits on HIV testing and antiretroviral therapy initiation: a cluster randomised trial in MalawiPitchaya P Indravudh, Katherine Fielding, Richard Chilongosi, et al.
Infection and Immunity|December 23, 2003
Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test designJohan Vekemans, Martin O C Ota, Jackson Sillah, et al.
American Journal of Respiratory and Critical Care Medicine|June 12, 2004
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold minersElizabeth L Corbett, Salome Charalambous, Vicky M Moloi, et al.
PLOS Global Public Health|August 8, 2024
Factors related to the utilization of digital adherence technologies in tuberculosis care: A qualitative study among adults in DS-TB treatment, health care providers and other key actors in TanzaniaBianca Gonçalves Tasca, Andrew Mganga, Chung Lam Leung, et al.
AIDS (London, England)|September 23, 2003
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?Gavin J Churchyard, Katherine Fielding, Salome Charalambous, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2025
Xpert MTB/RIF® cycle threshold as a marker of TB disease severity; Implications for TB treatment stratificationDaniel J Grint, Jasvir Dhillon, Philip D Butcher, et al.
The Lancet. Respiratory Medicine|March 19, 2021
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trialRobert S Wallis, Sibuse Ginindza, Trevor Beattie, et al.
Pageof 32